Press Releases
June 24, 2024
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial
DSMB Recommended Continuation with No Trial Modification
- DSMB Recommends Continuation without Modification for Third Time
- Safety Review Included 395 Patients
- Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate
- Low Event Rate Suggests Potential for Prolonged Survival
- Rapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected